ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.807,59
-0,40%
S&P 500
5.518,08
0,64%
US Dollar vs BRL
5,57073
1,25%
Bitcoin
60.791,11
-1,33%
Brent Oil
84,88
-0,63%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. ARS Pharmaceuticals Inc (SPRY)

  7. ARS Pharmaceuticals Inc (SPRY) Notícias

SPRY

ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SPRY
DataHoraFonteTítuloCódigoCompanhia
28/06/202407:30GlobeNewswire Inc.ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)NASDAQ:SPRYARS Pharmaceuticals Inc
17/06/202421:47Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SPRYARS Pharmaceuticals Inc
13/06/202417:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
10/05/202408:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
09/05/202417:05GlobeNewswire Inc.ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
30/04/202410:01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandNASDAQ:SPRYARS Pharmaceuticals Inc
03/04/202410:01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)NASDAQ:SPRYARS Pharmaceuticals Inc
21/03/202417:05GlobeNewswire Inc.ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
07/03/202418:05GlobeNewswire Inc.ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayNASDAQ:SPRYARS Pharmaceuticals Inc
06/03/202411:01GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:SPRYARS Pharmaceuticals Inc
26/02/202414:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
26/02/202411:01GlobeNewswire Inc.ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical studyNASDAQ:SPRYARS Pharmaceuticals Inc
22/02/202411:01GlobeNewswire Inc.ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024NASDAQ:SPRYARS Pharmaceuticals Inc
20/02/202411:01GlobeNewswire Inc.ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response LetterNASDAQ:SPRYARS Pharmaceuticals Inc
05/02/202411:01GlobeNewswire Inc.ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual MeetingNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202318:00GlobeNewswire Inc.ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202313:02GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
06/10/202310:57Dow Jones NewsARS Pharmaceuticals to Meet With FDA on Neffy RejectionNASDAQ:SPRYARS Pharmaceuticals Inc
06/10/202310:03GlobeNewswire Inc.ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)NASDAQ:SPRYARS Pharmaceuticals Inc
03/10/202310:03GlobeNewswire Inc.Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical ImmunologyNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202311:20Dow Jones NewsARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy SetbackNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202307:30Dow Jones NewsARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy SprayNASDAQ:SPRYARS Pharmaceuticals Inc
19/09/202323:49GlobeNewswire Inc.FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional StudyNASDAQ:SPRYARS Pharmaceuticals Inc
10/08/202317:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPRYARS Pharmaceuticals Inc
10/08/202317:00GlobeNewswire Inc.ARS Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
28/06/202317:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SPRYARS Pharmaceuticals Inc
20/06/202309:00GlobeNewswire Inc.ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
15/05/202310:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SPRYARS Pharmaceuticals Inc
15/05/202310:00GlobeNewswire Inc.ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
12/05/202309:55Dow Jones NewsARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs NeffyNASDAQ:SPRYARS Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SPRY

Seu Histórico Recente

USOTC
LRSRF
Latin Resources (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados